First Time Loading...
T

Talkmed Group Ltd
SGX:5G3

Watchlist Manager
Talkmed Group Ltd
SGX:5G3
Watchlist
Price: 0.4 SGD -1.23% Market Closed
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one 5G3 stock under the Base Case scenario is 0.33 SGD. Compared to the current market price of 0.4 SGD, Talkmed Group Ltd is Overvalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

5G3 Relative Value
Base Case
0.33 SGD
Overvaluation 19%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

6.3
P/S
P/S
Price to Sales
6.3
vs History
84
vs Industry
21
Median 3Y
6.8
Median 5Y
7.3
Industry
2.4
More Details
16.5
P/E
P/E
Price to Earnings
16.5
vs History
68
vs Industry
32
Median 3Y
17.3
Median 5Y
17
Industry
23.4
More Details
12.7
P/OCF
P/OCF
Price to OCF
12.7
vs History
80
vs Industry
30
Median 3Y
15.6
Median 5Y
15.5
Industry
15.5
More Details
13.1
P/FCFE
P/FCFE
Price to FCFE
13.1
vs History
92
vs Industry
30
Median 3Y
18.3
Median 5Y
18.3
Industry
23.2
More Details
5.9
P/B
P/B
Price to Book Value
5.9
vs History
47
vs Industry
13
Median 3Y
5.7
Median 5Y
5.9
Industry
2.3
More Details
5.3
EV/S
EV/S
Enterprise Value to Sales
5.3
vs History
85
vs Industry
23
Median 3Y
5.8
Median 5Y
6.2
Industry
2.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
More Details
10.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.6
vs History
69
vs Industry
32
Median 3Y
11.5
Median 5Y
11.6
Industry
12.6
More Details
11.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.4
vs History
71
vs Industry
36
Median 3Y
12.4
Median 5Y
12.4
Industry
17.2
More Details
10.7
EV/OCF
EV/OCF
Enterprise Value to OCF
10.7
vs History
82
vs Industry
37
Median 3Y
13.2
Median 5Y
13.5
Industry
15.3
More Details
10.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
10.8
vs History
90
vs Industry
33
Median 3Y
14.8
Median 5Y
14.6
Industry
19.8
More Details
20.1
EV/IC
EV/IC
Enterprise Value to IC
20.1
vs History
46
vs Industry
4
Median 3Y
18.9
Median 5Y
19.7
Industry
2
More Details

Multiples Across Competitors

5G3 Competitors Multiples
Talkmed Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Talkmed Group Ltd
SGX:5G3
530.2m SGD 6.3 16.5 10.6 11.4
US
Cigna Group
XMUN:CGN
90.8B EUR 0.5 27 9.7 12.9
US
Cigna Corp
NYSE:CI
97.3B USD 0.5 26.9 9.7 12.9
US
CVS Health Corp
NYSE:CVS
70.1B USD 0.2 9.6 8.7 8.7
US
Laboratory Corporation of America Holdings
NYSE:LH
16.9B USD 1.4 39.1 11.9 17.9
DE
Fresenius SE & Co KGaA
XETRA:FRE
15.6B EUR 0.7 -26.2 10.1 22.5
US
Quest Diagnostics Inc
NYSE:DGX
15.1B USD 1.6 17.9 10.7 14.5
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
10.9B EUR 0.6 21.8 6.7 15.8
DE
Fresenius Medical Care AG
XMUN:FME
11.5B EUR 0.6 23 6.9 16.3
US
DaVita Inc
NYSE:DVA
12B USD 1 14.7 8.3 11.9
US
Oak Street Health Inc
NYSE:OSH
9.5B USD 4.4 -18.6 -23.3 -21.5

See Also

Summary
5G3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
5G3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
5G3 stock valuation using valuation multiples.
Wall Street Estimates
5G3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
5G3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.